Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company ...

Pre-earnings options volume in Viking Therapeutics (VKTX) is normal with calls leading puts 9:4. Implied volatility suggests the market is ...

It has been about a month since the last earnings report for Viking Holdings (VIK). Shares have added about 13% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Viking Holdings Ltd stock has reached an all-time high, closing at 58.76 USD. The company, now valued at $25.85 billion, has caught investors’ attention with its impressive market performance.

Viking Therapeutics stock has already tripled in 2024, but Wall Street analysts think it has more room to run. Viking Therapeutics' lead candidate is an experimental weight management treatment that ...